Protein-based nanoplatform for detection of tumorigenic polyps in the colon via noninvasive mucosal routes.
Chun-Chieh ChenMo A BaikoghliR Holland ChengPublished in: Pharmaceutical patent analyst (2021)
The use of nanoparticulate systems to diagnose and treat tumors has gained momentum with the rapid development of nanomedicine. Many nanotheranostics fail due to insufficient bioavailability and low accumulation at the tumor site, resulting in undesirable side effects. We describe the use of an engineered hepatitis E viral nanoparticle (HEVNP) with enhanced bioavailability, tissue retention and mucosal penetration capacities. HEVNP is a modular nanocapsule that can encapsulate heterologous nucleotides, proteins and inorganic metals, such as ferrite oxide nanoparticles. Additionally, the exterior protruding arms of HEVNP is composed of loops that are used for chemical coupling of targeting and therapeutic peptides. We propose the use of HEVNP to target colorectal cancer (i.e., polyps) with imaging-guided delivery using colonoscopy.
Keyphrases
- oxide nanoparticles
- cancer therapy
- loop mediated isothermal amplification
- chronic rhinosinusitis
- ulcerative colitis
- drug delivery
- high resolution
- amino acid
- sars cov
- photodynamic therapy
- human health
- sensitive detection
- room temperature
- health risk
- real time pcr
- binding protein
- protein protein
- health risk assessment
- risk assessment
- saccharomyces cerevisiae
- drug release
- mass spectrometry
- colorectal cancer screening
- iron oxide
- ionic liquid